Business Context and Reporting Period
Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: BioLife develops and supplies bioproduction tools and services for the cell and gene therapy industry, including biopreservation media, automated thawing devices, and storage solutions. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Total Revenue | $28,328 | $29,237 | $55,107 | $58,419 |
| Operating Loss | $(2,795) | $(10,628) | $(6,956) | $(19,260) |
| Net Loss (Continuing Ops) | $(7,146) | $(5,518) | $(11,358) | $(14,239) |
| Net Loss (Including Discontinued Ops) | $(20,719) | $(10,199) | $(30,940) | $(23,913) |
| Cash & Equivalents (End of Period) | $22,014 | $21,431 | $22,014 | $21,431 |
| Total Debt (Current + Long-term) | $21,065 | $25,144 | $21,065 | $25,144 |
| Operating Cash Flow (6M) | $1,984 | $(10,430) | $1,984 | $(10,430) |
Note: Revenue and expense figures exclude discontinued operations unless specified. Net Loss includes a significant loss from the divestiture of Global Cooling.
Material Changes vs. Prior Period
- Divestiture of Global Cooling: On April 17, 2024, the company sold its Global Cooling subsidiary. This resulted in a $8.9 million loss on disposal and reclassified Global Cooling results as discontinued operations. The divestiture included a reduction in force of 47 employees.
- Revenue Decline: Total revenue decreased 3% in Q2 2024 and 6% in the first six months of 2024 compared to the prior year.
- Product Revenue: Down 6% (Q2) and 11% (6M), driven by customer destocking and reduced biotech funding.
- Service Revenue: Increased 6% (Q2) and 16% (6M), primarily due to expansion of SciSafe storage services.
- Rental Revenue: Increased 14% (Q2) and 13% (6M) due to new customer acquisition.
- Expense Reduction: Operating expenses decreased 22% in Q2 and 20% in the first six months of 2024. This was driven by lower headcount, reduced professional fees, and decreased R&D milestone payments.
- Equity Investment Impairment: The company recorded a $4.1 million impairment charge on its equity investment in iVexSol, Inc., due to a going concern trigger and unrecoverable carrying value.
- Cost of Revenue Efficiency: Cost of revenue as a percentage of revenue improved to 49% in 2024 from 65-69% in 2023, attributed to operational efficiencies and favorable product mix.
Guidance, Outlook, and Risks
- Liquidity: As of June 30, 2024, the company held $36.9 million in cash, cash equivalents, and available-for-sale securities. Management believes this is sufficient to meet liquidity needs for at least the next 12 months.
- Debt Obligations: The company has a $20 million Term Loan maturing in June 2026. Interest-only payments are currently in effect. The company is in compliance with all covenants.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in internal control over financial reporting (e.g., insufficient qualified resources, ineffective risk assessment, and inadequate accounting procedures). Remediation plans are ongoing.
- Contingencies: The company has an estimated sales tax liability of approximately $4.4 million related to periods 2019-2023, with timing of satisfaction uncertain.
- Outlook: No specific financial guidance was provided in the text. Management notes that results are not necessarily indicative of future performance due to economic uncertainty and high interest rates.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the long-term strategic impact of the Global Cooling divestiture and the accuracy of the $8.9 million loss calculation.
- Internal Control Remediation: Review the specific steps being taken to address the material weaknesses in internal controls and the timeline for achieving effectiveness.
- Equity Investment Valuation: Assess the remaining portfolio of equity investments (e.g., PanTHERA) for potential further impairment risks given the iVexSol write-down.
- Sales Tax Liability: Monitor the resolution of the $4.4 million estimated sales tax liability and any potential additional assessments.
- Revenue Concentration: Note that one customer (Customer A) represented 15% of revenue in Q2 2024, and CryoStor products accounted for 50% of product revenue.